• FirefoxInstall the new Firefox »
  •  Dow Down0.58% Nasdaq Down0.26%

    More On RDHL



    News & Info


    Analyst Coverage



    RedHill Biopharma Ltd. (RDHL)

    14.20 Up 0.01(0.07%) Mar 4, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    RedHill Biopharma Ltd.
    21 Ha
    Tel Aviv, 64739
    Israel - Map
    Phone: 972 3 541 3131
    Fax: 972 3 541 3144
    Website: http://www.redhillbio.com

    Index Membership:N/A
    Full Time Employees:8

    Business Summary 

    RedHill Biopharma Ltd., an Israeli biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company’s pipeline of therapeutic candidates include RHB-105 intended for the eradication of Helicobacter pylori infection that is under Phase III study; RHB-104 for the treatment of Crohn's disease, which is under Phase III study; BEKINDA for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and gastroenteritis and gastritis that is under phase III study; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract. Its pipeline of therapeutic candidates also comprise MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers that has completed Phase II-stage; RP101, a Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. The company was founded in 2009 and is based in Tel Aviv, Israel.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on RedHill Biopharma Ltd.

    Key Executives 
    Mr. Dror Ben-Asher , 49
    Chairman and Chief Exec. Officer
    Mr. Ori Shilo , 49
    Deputy Chief Exec. Officer of Fin. & Operations and Director
    Dr. Reza Fathi Ph.D., 60
    Sr. VP of R&D
    Mr. Gilead Raday MPhil, MSc, 40
    Sr. VP of Corp. & Product Devel.
    Mr. Guy Goldberg J.D., 39
    Chief Bus. Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.